MX2019010452A - Fabricacion de un producto farmaceutico cristalino. - Google Patents
Fabricacion de un producto farmaceutico cristalino.Info
- Publication number
- MX2019010452A MX2019010452A MX2019010452A MX2019010452A MX2019010452A MX 2019010452 A MX2019010452 A MX 2019010452A MX 2019010452 A MX2019010452 A MX 2019010452A MX 2019010452 A MX2019010452 A MX 2019010452A MX 2019010452 A MX2019010452 A MX 2019010452A
- Authority
- MX
- Mexico
- Prior art keywords
- manufacture
- pharmaceutical product
- crystalline pharmaceutical
- crystalline
- particles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención actual se refiere a partículas cristalinas de N-((S)-1-(3-(3-cloro-4-cianofenil)-1Hpirazol- 1-il)-propan-2-il)-5-(1-hidroxietil)-1H-pirazol-3-carboxamida (I) que tienen un área de superficie específica (SSA) en el intervalo desde alrededor de 8 hasta alrededor de 16 m2/g, preferiblemente desde alrededor de 10 hasta alrededor de 15 m2/g, y al método para la preparación de tales partículas. El Compuesto (I) es un modulador del receptor de andrógeno (AR) potente que es útil como un medicamento por ejemplo en el tratamiento del cáncer de próstata.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20175202 | 2017-03-07 | ||
PCT/FI2018/050143 WO2018162793A1 (en) | 2017-03-07 | 2018-02-27 | Manufacture of a crystalline pharmaceutical product |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019010452A true MX2019010452A (es) | 2019-10-15 |
Family
ID=61599196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019010452A MX2019010452A (es) | 2017-03-07 | 2018-02-27 | Fabricacion de un producto farmaceutico cristalino. |
Country Status (13)
Country | Link |
---|---|
US (1) | US11168058B2 (es) |
EP (1) | EP3592732A1 (es) |
JP (1) | JP7157071B2 (es) |
KR (1) | KR20190126111A (es) |
CN (1) | CN110382467A (es) |
AU (1) | AU2018229817B2 (es) |
BR (1) | BR112019018458A2 (es) |
CA (1) | CA3055019A1 (es) |
CL (2) | CL2019002540A1 (es) |
EA (1) | EA201992103A1 (es) |
MX (1) | MX2019010452A (es) |
UA (1) | UA126071C2 (es) |
WO (1) | WO2018162793A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021515040A (ja) | 2018-02-27 | 2021-06-17 | サンド・アクチエンゲゼルシヤフト | ダロルタミドの結晶形態ii |
WO2021001603A1 (en) | 2019-07-02 | 2021-01-07 | Orion Corporation | Pharmaceutical composition of darolutamide |
WO2022036782A1 (zh) * | 2020-08-18 | 2022-02-24 | 拜耳消费者护理股份有限公司 | 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途 |
WO2022144926A1 (en) * | 2020-12-31 | 2022-07-07 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide |
WO2023161458A1 (en) | 2022-02-28 | 2023-08-31 | Química Sintética, S.A. | Crystalline form of darolutamide |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090304755A1 (en) * | 2005-10-27 | 2009-12-10 | Raghu Rami Reddy Kasu | Pharmaceutical formulation of losartan |
US8883307B2 (en) * | 2007-05-28 | 2014-11-11 | Mitsubishi Shoji Foodtech Co., Ltd. | Spherical particle of crystalline mannitol |
CN102438979A (zh) * | 2009-03-12 | 2012-05-02 | 麦迪凯姆股份公司 | 苯甲酰基苯乙酰胺衍生物的新型晶体 |
AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
KR101958177B1 (ko) | 2011-04-21 | 2019-03-15 | 오리온 코포레이션 | 안드로겐 수용체 조절성 카복스아미드 |
KR20140030169A (ko) * | 2011-05-04 | 2014-03-11 | 머크 샤프 앤드 돔 코포레이션 | 약물 물질, 제약 조성물 및 그의 제조 방법 |
EP3250554B1 (en) * | 2015-01-30 | 2022-05-18 | Orion Corporation | A carboxamide derivative and its diastereomers in stable crystalline form |
SI3495352T1 (sl) | 2016-08-26 | 2021-08-31 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Kristalinične oblike antagonista androgenskih receptorjev, postopek njihove priprave in njihova uporaba |
-
2018
- 2018-02-27 UA UAA201910164A patent/UA126071C2/uk unknown
- 2018-02-27 US US16/491,642 patent/US11168058B2/en active Active
- 2018-02-27 AU AU2018229817A patent/AU2018229817B2/en active Active
- 2018-02-27 EA EA201992103A patent/EA201992103A1/ru unknown
- 2018-02-27 MX MX2019010452A patent/MX2019010452A/es unknown
- 2018-02-27 JP JP2019548560A patent/JP7157071B2/ja active Active
- 2018-02-27 CN CN201880016135.3A patent/CN110382467A/zh active Pending
- 2018-02-27 WO PCT/FI2018/050143 patent/WO2018162793A1/en unknown
- 2018-02-27 KR KR1020197029193A patent/KR20190126111A/ko active IP Right Grant
- 2018-02-27 CA CA3055019A patent/CA3055019A1/en active Pending
- 2018-02-27 BR BR112019018458A patent/BR112019018458A2/pt unknown
- 2018-02-27 EP EP18709661.5A patent/EP3592732A1/en active Pending
-
2019
- 2019-09-04 CL CL2019002540A patent/CL2019002540A1/es unknown
-
2023
- 2023-09-20 CL CL2023002780A patent/CL2023002780A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018229817A1 (en) | 2019-10-24 |
JP7157071B2 (ja) | 2022-10-19 |
CN110382467A (zh) | 2019-10-25 |
KR20190126111A (ko) | 2019-11-08 |
CL2023002780A1 (es) | 2024-01-26 |
EA201992103A1 (ru) | 2020-01-24 |
JP2020510018A (ja) | 2020-04-02 |
UA126071C2 (uk) | 2022-08-10 |
EP3592732A1 (en) | 2020-01-15 |
AU2018229817B2 (en) | 2021-09-30 |
CA3055019A1 (en) | 2018-09-13 |
WO2018162793A1 (en) | 2018-09-13 |
US20200039940A1 (en) | 2020-02-06 |
US11168058B2 (en) | 2021-11-09 |
BR112019018458A2 (pt) | 2020-04-14 |
CL2019002540A1 (es) | 2020-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019010452A (es) | Fabricacion de un producto farmaceutico cristalino. | |
AU2018231032A8 (en) | JAK inhibitors containing a 4-membered heterocyclic amide | |
WO2017204445A3 (ko) | Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
PH12019502577A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
JO3459B1 (ar) | تركيبات صيدلانية لعلاج مرض الزهايمر | |
PH12017500503A1 (en) | Mono- or di-substituted indoles as dengue viral replication inhibitors | |
WO2016100162A3 (en) | 5,5-bicyclic oxazole orexin receptor antagonists | |
JOP20180025A1 (ar) | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك | |
PH12019502095A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
PH12019502559A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
MY185488A (en) | Process for the preparation of androgen receptor antagonists and intermediates thereof | |
PH12018502314A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
AU2020288559A8 (en) | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists | |
ZA202001780B (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
MX2019012116A (es) | Agentes antifungicos utilizados en combinacion. | |
ZA202002129B (en) | Oral bendamustine formulations | |
PH12021550258A1 (en) | Cdk8/19 inhibitors | |
PH12020500393A1 (en) | Mpges-1 inhibitor for the treatment of osteoarthritis pain | |
NZ727251A (en) | Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s |